Link Pharma Chem Ltd Stock Price Today (NSE: LINKPH)
Fundamental Score
Link Pharma Chem Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Link Pharma Chem Ltd share price today is ₹24.00, down 4.00% on NSE/BSE as of 16 April 2026. Link Pharma Chem Ltd (LINKPH) is a Small-cap company in the Commodity Chemicals sector with a market capitalisation of ₹15.33 (Cr). The 52-week high for LINKPH share price is ₹42.80 and the 52-week low is ₹21.00. The company has a Return on Equity (ROE) of -7.81% and a debt-to-equity ratio of 0.62.
Link Pharma Chem Ltd Share Price Chart — NSE/BSE Historical Performance
AI Research Briefing
Powered by Gemini · 2026-04-13
Short-term technical bounce in a fundamentally challenged micro-cap commodity chemical company; fade the rally.
⚡ WHAT'S HAPPENING NOW (last 2-4 weeks): Link Pharma Chem Ltd's investment rating was upgraded from Strong Sell to Sell on April 9, 2026, driven by improved technicals and valuation. The stock closed at ₹28.74 on April 9, 2026, up 8.29% from the previous close. The company saw a weekly gain of 7.42%, closing at ₹28.68 on April 10, 2026, outperforming the Sensex. 🧠 CORE STORY (THE REAL GAME): Link Pharma is a micro-cap commodity chemical company. The market appears to be reacting to short-term valuation improvements and technical upgrades, but the core narrative remains tied to the cyclical nature of the commodity chemicals sector and the company's weak long-term financials. 🔥 WHAT IS DRIVING THE STOCK: 1. **Valuation Upgrade:** A shift to 'very attractive' valuation on April 6, 2026, due to a favorable price-to-earnings ratio of 76.12 and a price-to-book value of 0.82. 2. **Technical Upgrade:** Markets Mojo upgraded the stock from 'Strong Sell' to 'Sell' based on improved technical indicators. ⚖️ BULL vs BEAR: Bull: Short-term traders might see an opportunity in the improved technicals and valuation, potentially leading to further price appreciation. Bear: Long-term fundamentals remain weak, with negative ROE and ROCE. The company's interest coverage is also negative, and it operates in a highly competitive and cyclical industry. Micro-cap status amplifies liquidity risk. 💣 WHAT MARKET IS PRICING: The market is pricing in a short-term recovery based on valuation and technical improvements. This could fade quickly if fundamental weaknesses persist or if the commodity chemicals cycle turns. 🎯 BOTTOM LINE: Link Pharma remains a high-risk micro-cap play with weak fundamentals; any rally is a chance to reduce exposure.
- Valuation upgrade
- Technical upgrade
- Short-term price momentum
- New order wins
- Significant improvement in quarterly earnings
- Industry consolidation
- Micro-cap liquidity risk
- Negative ROE and ROCE
- Negative interest coverage
No significant FII/DII activity reported.
Indian chemical production is projected to increase by 10.9% in 2026, driven by robust domestic demand and government support.
Free Cash Flow 5Y: ₹0.09 Cr. Profit not consistently converting to cash.
Near-term price may fluctuate based on technical factors, but long-term sustainability is questionable due to weak fundamentals. Focus on quarterly results and debt management.
Primary Thesis Risk
Inability to improve profitability and manage debt will lead to collapse.
For educational purposes only. Not investment advice. Consult a SEBI-registered advisor before investing.
Returns & Performance
ROE
ROCE
OPM (5Y)
Div Yield
Link Pharma Chem Ltd Valuation Check
P/E Ratio
Industry P/E
Market Cap
Growth Engine
Profit Growth (Q)
Sales Growth (Q)
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Balance Sheet Health
Debt to Equity
Int. Coverage
Free Cash Flow (5Y)
Shareholding
Promoter
FII
DII
Pledged
Institutional Deep-Dive
Bull Run Research Hub
Link Pharma Chem Share Price: A Financial Snapshot in a Fluctuating Commodity Chemicals Landscape
The volatility inherent in the commodity chemicals sector makes understanding individual company performance crucial for stakeholders. Currently, the Link Pharma Chem share price sits at ₹29.95. However, a deeper dive reveals a more complex picture. The absence of a Price-to-Earnings (PE) ratio immediately suggests potential challenges in profitability, which necessitates further investigation of its financial health compared to competitors in the market.
One key metric that warrants attention is Link Pharma Chem's Return on Capital Employed (ROCE), currently at -3.0%. This negative ROCE signals that the company is not generating sufficient returns from its invested capital. A low or negative ROCE directly impacts the company's economic moat – its ability to sustain a competitive advantage. A strong moat typically protects a company's profitability and market share, but a negative ROCE suggests Link Pharma Chem struggles to create or maintain such a protective barrier. In comparison, understanding the management quality and strategic decision-making at a peer like
AG Ventures can provide valuable context, potentially highlighting areas where Link Pharma Chem could improve its operational efficiency and capital allocation.The company's performance should also be benchmarked against its other sector peers like RNPLSM and Ritesh Intl. A comparative analysis of these firms will paint a more complete picture of relative financial strength, profitability, and growth potential within the industry. Further investigation into Link Pharma Chem's debt levels, cash flow, and cost structure is crucial to understand the drivers behind the negative ROCE and its overall financial stability.
This financial analysis, focusing on the Link Pharma Chem share price and underlying financial metrics, is part of a comprehensive 80-parameter fundamental audit, verified by Sweta Mishra. The intent is to provide an objective observation of the company's current financial standing based on publicly available data.
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Link Pharma Chem Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of LINKPH across key market metrics for learning purposes.
Positive Indicators
4 factors identified
Robust Profit Growth (106.45%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture.
Strong Revenue Growth (31.04%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential.
Balanced Promoter Holding (51.49%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
7 factors identified
Below-Average Return on Equity (-7.81%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Suboptimal ROCE (-3.00%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.
Margin Pressure Concerns (4.87%)
Observation: Operating margins are below industry standards.
Analysis: OPM <5% may indicate pricing pressures or cost management challenges.
Limited Growth History (-0.03% CAGR)
Observation: Below-average 5-year sales growth trajectory.
Analysis: Low sales CAGR may indicate mature markets or limited growth opportunities.
Weak Interest Coverage (-0.50x)
Observation: Limited ability to service debt obligations from earnings.
Analysis: Low interest coverage raises concerns about financial stability.
Limited Institutional Interest (FII+DII: 0.02%)
Observation: Low institutional participation may affect liquidity.
Analysis: Limited institutional interest may indicate size constraints or visibility issues.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Link Pharma Chem Ltd Financial Statements
Comprehensive financial data for Link Pharma Chem Ltd including income statement, balance sheet and cash flow
About LINKPH (Link Pharma Chem Ltd)
Link Pharma Chem Ltd is a prominent manufacturer of high-quality commodity chemicals, playing a critical role in supplying essential building blocks for diverse industries. Focused... on providing consistent and reliable raw materials, the company leverages advanced production techniques to deliver core chemical components to manufacturers around the globe. Link Pharma Chem is committed to upholding stringent quality control measures, ensuring that its commodity chemicals meet rigorous industry standards and client specifications. Through strategic sourcing and efficient supply chain management, Link Pharma Chem offers competitive pricing and timely delivery, establishing itself as a trusted partner for businesses seeking dependable chemical inputs. The company specializes in the production of key intermediates used in a broad range of applications. These include the foundational components necessary for creating polymers, solvents, and other critical industrial products. Link Pharma Chem’s commitment to innovation drives continuous improvement in its manufacturing processes, optimizing yields and minimizing environmental impact. Furthermore, the company maintains a dedicated team of experts who provide technical support and guidance to customers, ensuring seamless integration of its products into their respective manufacturing processes. This customer-centric approach solidifies Link Pharma Chem's position as a solution provider in the commodity chemical market. Link Pharma Chem Ltd prioritizes sustainability and environmental responsibility in its operations. It invests in technologies that minimize waste generation and reduce its carbon footprint. By adhering to strict environmental regulations and implementing eco-friendly practices, the company strives to operate as a responsible steward of the environment. This commitment to sustainability not only benefits the planet but also enhances the company's reputation and strengthens its relationships with environmentally conscious customers. As the demand for sustainable chemical solutions grows, Link Pharma Chem is well-positioned to meet the evolving needs of the industry.
Company Details
Key Leadership
Corporate Events
LINKPH Share Price: Frequently Asked Questions
What is the current share price of Link Pharma Chem Ltd (LINKPH)?
As of 16 Apr 2026, 11:00 am IST, Link Pharma Chem Ltd share price is ₹24.00. The LINKPH stock has a market capitalisation of ₹15.33 (Cr) on NSE/BSE.
Is LINKPH share price Overvalued or Undervalued?
LINKPH share price is currently trading at a P/E ratio of 0.00x, compared to the industry average of 20.98x. Based on this relative valuation, the Link Pharma Chem Ltd stock appears to be Fairly Valued against its sector peers.
What is the 52-week high and low of LINKPH share price?
The 52-week high of LINKPH share price is ₹42.80 and the 52-week low is ₹21.00. These values are updated daily from NSE/BSE price data.
What factors affect the Link Pharma Chem Ltd share price?
Key factors influencing LINKPH share price include quarterly earnings growth (Sales Growth: 31.04%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is Link Pharma Chem Ltd a good stock for long-term investment?
Link Pharma Chem Ltd shows a 5-year Profit Growth of N/A% and an ROE of -7.81%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.62 before investing in LINKPH shares.
How does Link Pharma Chem Ltd compare with its industry peers?
Link Pharma Chem Ltd competes with major peers in the Commodity Chemicals. Investors should compare LINKPH share price P/E of 0.00x and ROE of -7.81% against the industry averages to determine competitive standing.
What is the P/E ratio of LINKPH and what does it mean?
LINKPH share price has a P/E ratio of N/Ax compared to the industry average of 20.98x. Investors pay ₹N/A for every ₹1 of annual earnings.
How is LINKPH performing according to Bull Run's analysis?
LINKPH has a Bull Run fundamental score of 26/100, indicating concerns requiring careful analysis. This comprehensive rating is based on 15+ financial parameters.
What sector and industry does LINKPH belong to?
LINKPH operates in the Commodity Chemicals industry. This classification helps understand the competitive landscape and sector-specific trends affecting Link Pharma Chem Ltd share price.
What is Return on Equity (ROE) and why is it important for LINKPH?
LINKPH has an ROE of -7.81%, which suggests challenges in generating returns from shareholders equity. ROE measures how efficiently Link Pharma Chem Ltd generates profits from shareholders capital.
How is LINKPH debt-to-equity ratio and what does it indicate?
LINKPH has a debt-to-equity ratio of 0.62, which indicates moderate leverage that should be monitored.
What is LINKPH dividend yield and is it a good dividend stock?
LINKPH offers a dividend yield of 0.00%, meaning you receive ₹0.00 annual dividend for every ₹100 invested in Link Pharma Chem Ltd shares.
How has LINKPH share price grown over the past 5 years?
LINKPH has achieved 5-year growth rates of: Sales Growth -0.03%, Profit Growth N/A%, and EPS Growth N/A%.
What is the promoter holding in LINKPH and why does it matter?
Promoters hold 51.49% of LINKPH shares, with 0.00% pledged. High promoter holding often indicates strong management confidence in Link Pharma Chem Ltd.
What is LINKPH market capitalisation category?
LINKPH has a market capitalisation of ₹15 crores, placing it in the Small-cap category.
How volatile is LINKPH stock?
LINKPH has a beta of N/A. A beta > 1 suggests the Link Pharma Chem Ltd stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is LINKPH operating profit margin trend?
LINKPH has a 5-year average Operating Profit Margin (OPM) of 4.87%, indicating the company's operational efficiency.
How is LINKPH quarterly performance?
Recent quarterly performance shows Link Pharma Chem Ltd YoY Sales Growth of 31.04% and YoY Profit Growth of 106.45%.
What is the institutional holding pattern in LINKPH?
LINKPH has FII holding of 0.00% and DII holding of 0.02%. Significant institutional holding often suggests professional confidence in the Link Pharma Chem Ltd stock.